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662Effect of Ex Vivo Culture of CD341 Bone Marrow Cells
on Immune Reconstitution of XSCID Dogs Following
Allogeneic Bone Marrow Transplantation
Douglas R. Kennedy,1 Kyle McLellan,1 Peter F. Moore,2 Paula S. Henthorn,1 Peter J. Felsburg1Successful genetic treatment of most primary immunodeficiencies or hematological disorders will require
the transduction of pluripotent, self-renewing hematopoietic stem cells (HSC) rather than their progeny
to achieve enduring production of genetically corrected cells and durable immune reconstitution. Current
ex vivo transduction protocols require manipulation of HSC by culture in cytokines for various lengths of
time depending upon the retroviral vector that may force HSC to enter pathways of proliferation, and pos-
sibly differentiation, which could limit their engraftment potential, pluripotentiality and long-term repopulat-
ing capacity.We have compared the ability of normal CD341 cells cultured in a standard cytokine cocktail for
18 hours or 4.5 days to reconstitute XSCID dogs following bone marrow transplantation in the absence of
any pretransplant conditioning with that of freshly isolated CD341 cells. CD341 cells cultured under stan-
dard g-retroviral transduction conditions (4.5 days) showed decreased engraftment potential and ability to
sustain long-term thymopoiesis. In contrast, XSCID dogs transplanted with CD341 cells cultured for
18 hours showed a robust T cell immune reconstitution similar to dogs transplanted with freshly isolated
CD341 cells, however, the ability to sustain long-term thymopoiesis was impaired. These results
emphasize the need to determine ex vivo culture conditions that maintain both the engraftment potential
and ‘‘stem cell’’ potential of the cultured cells.
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A prerequisite for any ex vivo approach to hemato-
poietic stem cell (HSC) gene therapy is the ability of
the transduced HSC to successfully engraft in the re-
cipient following their reinfusion. The major limita-
tion of the ex vivo approach to gene therapy is the
need for ex vivo manipulation of HSC with culturing
in cytokines for various lengths of time depending
upon the retroviral vector. CD34, a cell surface glyco-
protein, is an antigen expressed on a subpopulation of
hematopoietic cells that contain both stem cells, pre-
sumably pluripotent stem cells, and early committed
progenitors that are capable of multilineage engraft-
ment in humans, mice, nonhuman primates, and,
more recently, dogs [1-8]. It is clear from a large1Department of Clinical Studies, School of Veterinary
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of cells within the CD341 population is both
pluripotent and capable of self-renewal, and selection
based upon CD34 does not deplete the graft of signif-
icant numbers of HSCs. Therefore, enumeration of
CD341 cells is the current ‘‘surrogate’’ for determin-
ing the stem cell content of a human, nonhuman pri-
mate and canine bone marrow grafts and are the
current targets for human and canine gene therapy
involving diseases of the hematopoietic system.
Because g-retroviruses require active replication of
the target cells for transduction, the typicalg-retroviral
ex vivo transduction protocol used in human gene ther-
apy clinical trials consists of a one to two day pre-
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able attention as potential vectors for HSC, because
they have been shown to be capable of transducing qui-
escent CD341 cells, however maximal transduction oc-
curs as the cell enters G1 of the cell cycle [16,17].
Therefore, most studies use either an 18 hour (over-
night) or 48 hour transduction protocol in the presence
of various cytokine cocktails. As HSCs are typically
quiescent, ex vivo culture in cytokines that allow for
gene transfer to occur may force HSCs to enter path-
ways of proliferation, and possibly differentiation,
that could limit their engraftment potential, pluripo-
tentiality, and long-term repopulating capacity. Cur-
rently, the most controversial and important issue
regarding the clinical use of ex vivo manipulated cells
is the question of whether exhaustion of stem cells
might result from growth factor stimulation ex vivo,
which has considerable significance for both gene ther-
apy and HSC expansion protocols [18].
Over the past few years, evidence has accumulated
that cultured HSC have a reduced ability to engraft
in murine, xenogeneic, and large animal transplant
models. These animal studies were performed in recip-
ients following pretransplant conditioning that is
known to damage bone marrow stromal cells [19-21]
and decrease HSC homing to or survival in the bone
marrow following transplantation [22].
Competitive repopulation studies in mice have
revealed significantly reduced engraftment with ex-
panded cells compared with freshly isolated bone marrow
(BM) cells [23,24]. Transplantation of ex vivo cultured
autologous BM CD341 cells in myeloablated baboons
resulted in delayed short-term engraftment (recovery of
normal neutrophil and platelet counts) compared to
freshly isolated BM CD341 cells [25]. Autologous trans-
plantation of irradiated cats with cultured bone marrow
cells resulted in an engraftment rate of 40% compared
with 100% for noncultured cells [26].
Xenotransplantation of cultured human cord
blood (CB) cells in SCID or NOD/SCID mice have
been reported to result in delayed and significantly re-
duced engraftment compared with fresh CD341 cells
[27-33]. When fresh and expanded human CB
CD341 cells were transplanted together in a competi-
tive repopulation assay, the fresh CD341 cells signifi-
cantly out-competed the expanded cells [34]. An
important finding from these xenogeneic studies is
that the reduced in vivo repopulating capacity was ev-
ident as early as 24 to 48 hours in culture [29,30,33].
None of the previous studies have evaluated the ef-
fect of ex vivo culture of HSC on engraftment in the
absence of pretransplant conditioning or in a large an-
imal model of a relevant human disease, or on the
reconstitution of immune function. We have previ-
ously shown that freshly isolated bone marrow
CD341 cells from normal dog leukocyte antigen
(DLA) identical donors are capable of sustained Band T cell immune reconstitution of XSCID dogs fol-
lowing allogeneic BMT without any pretransplant
conditioning [8]. The purpose of this study was to de-
termine the effect of short-term ex vivo culture, similar
to that used for g-retroviral and lentiviral ex vivo trans-
duction, of purified bone marrow CD341 cells on their
ability to reconstitute normal T cell function and long-
term thymopoiesis in unconditioned XSCID dogs.MATERIALS AND METHODS
Dogs
The XSCID dogs used in this study were derived
from a breeding colony established from a single car-
rier female [35,36]. All affected dogs have the same
gc mutation, a four bp deletion in exon 1, and were di-
agnosed shortly after birth by a PCR based mutation
detection assay using DNA isolated from whole blood
[36,37]. DLA-matched or DLA-haploidentical normal
littermate donors for transplantation were determined
by PCR assay for highly polymorphic major histocom-
patibility complex (MHC) class I and class II microsa-
tellite marker polymorphisms [38-40].
Bone Marrow Preparation
Bone marrow cells were collected from normal lit-
termate donors following euthanasia by removing
a segment of the femur, flushing the marrow into a ster-
ile petri dish containing HBSS without calcium and
magnesium (Mediatech, Fisher Scientific, Philadel-
phia, PA), and filtered through a fine mesh filter
[8,36]. The cells were centrifuged and washed twice
in HBSS and resuspended in PBS for isolation of
CD341 cells. Isolation of bone marrow CD341 cells
was performed as previously described [8]. Briefly, un-
fractionated marrow cells were resuspended at a final
concentration of 1  108 cells/ml in a PBS solution
containing 2% horse serum and incubated with anti-
canine CD34 antibody 1H6 at 20 mg/108 cells [6].
Cells were incubated with anti-mouse IgG MACS
magnetic micro-beads followed by selection on vario-
MACS columns according to the manufacturer’s pro-
tocol (Miltenyi, Auburn, CA). Aliquots of positively
selected cells were labeled with phycoerythrin (PE)
labeled streptavidin (Jackson Immunoresearch, West
Grove, PA) and analyzed on a FACSCalibur flow cy-
tometer (Becton Dickinson, San Jose, CA) to deter-
mine the purity of the eluted cells. The purity of the
cells was .96%.
CD341 Cultures and Stimulation
On day 1, purified CD341 cells were placed in
Human Dexter Medium (HDM) containing 72%
isocove’s DMEM (Mediatech, Fisher Scientific, Phila-
delphia, PA), 12.5% fetal bovine serum (FBS), 12.5%
664 Biol Blood Marrow Transplant 15:662-670, 2009D. R. Kennedy et al.horse serum, 1% Penicillin-Streptomycin (Invitrogen,
Carlsbad, CA), 1% sodium pyruvate (Mediatech, Fisher
Scientific, Philadelphia,PA), 10 uM b-mercaptoethanol
and 1 uM hydrocortisone (Sigma Chemical, St. Louis,
MO), stimulated with 100 ng/ml canine granulocye-col-
ony-stimulating factor (G-CSF), 100 ng/ml canine stem
cell factor (SCF), 100ng/ml human FLT-3 ligand
(FLT3-L) (all kindly supplied by Amgen, Thousand
Oaks, CA), and 50 ng/ml human thrombopoietin
(TPO; PeproTech, Rocky Hill, NJ) and plated in
75 mm 117 mm single well plates (Nalge Nunc Inter-
national, Rochester, NY) at 4  105 cells/cm2. For cells
following the g-retroviral vector transduction protocol,
plates were incubated for 2 days at 37 C, 5% CO2. On
days 3 and 4, cells were washed once, fresh media and cy-
tokines were added, and plates were incubated 4 hours at
37C, 5% CO2. After the 4 hour incubation on day 4,
cells were washed twice in saline and a cell count was
taken. For cells following the lentiviral vector transduc-
tion protocol, freshly isolated CD341 cells were incu-
bated in HDM and the same cytokine cocktail describe
above overnight at 37C, 5% CO2. After the overnight
incubation, cells were washed twice in saline and a cell
count was taken. An aliquot of CD341 cells from each
set was labeled with PE-labeled streptavidin (Jackson Im-
munoresearch, West Grove, PA) and analyzed on
a FACSCalibur flow cytometer (Becton Dickinson, San
Jose, CA) to determine the purity of the CD341 cells.
Bone Marrow Transplantation
Ten XSCID dogs were transplanted with freshly
isolated DLA-matched CD341 bone marrow cells, in-
cluding 5 from a previous study [8] and 5 unique to this
current study, and 6 XSCID dogs were transplanted
with freshly isolated DLA-haploidentical CD341
bone marrow cells. Four XSCID dogs were trans-
planted with CD341 bone marrow cells cultured for
4.5 days, and two XSCID dogs were transplanted
with CD341 bone marrow cells cultured for 18 hours
(Table 1). All XSCID dogs were\2 weeks of age at the
time of transplantation. None of the dogs received any
pretransplant conditioning.
Flow Cytometry
Quantitation of peripheral blood lymphocyte sub-
populations was determined on EDTA blood samples
using a standard whole blood staining and lysis proto-Table 1. Dose of Cultured CD34 + Bone Marrow Cells.
Dog Donor DLA CD34 Purity (%) Dose Length of Culture
R1789 Matched 96.3 3.2  107/kg 4.5 days
X299 Haploidentical 93.9 3.5  107/kg 4.5 days
R1824 Haploidentical 97.1 3.0  107/kg 4.5 days
R1826 Matched 97.1 3.0  107/kg 4.5 days
R1844 Matched 95.6 3.0  107/kg 18 hours
R1847 Haploidentical 95.6 3.0  107/kg 18 hourscol [41]. The murine monoclonal antibody (mAb) used
in this study were FITC- or PE-labeled CD3
(CA17.3G9), CD4 (CA13.1E4), CD8 (CA9.JD3),
CD21 (CA2.1D6), and CD45RA (CA4.1D3) [42,43].
Analysis gates were adjusted to 1% positive stain-
ing with directly labeled isotype controls. For each
sample, 10,000 cells were analyzed using a Becton
Dickinson FACSCalibur (Becton Dickinson, San
Jose, CA).
Proliferation Assay
The response of peripheral blood lymphocytes to
in vitro mitogenic stimulation with PHA-P (5 mg/ml;
Sigma, St. Louis, MO) was performed as previously
described using a flow cytometric bromodeoxyuridine
(BrdU) assay (BD Bioscience, San Jose, CA) for assess-
ing cell proliferation as per manufacturer’s instruc-
tions [41]. Secondary staining was performed using
an allophycocyanin (APC)-labeled anti-mouse IgG1
antibody for flow cytometric detection.
T Cell Receptor Excision (TREC) Assay
DNA was purified from peripheral whole blood us-
ing Generation DNA purification kit (Gentra Systems,
Minneapolis, MN) according to the manufacturers in-
structions. To detect signal joint TRECs, a real-time
quantitative PCR method was performed on the 7500
Real-time PCR system (Applied Biosystems, Branch-
burg, NJ). Each PCR reaction was performed in a
50 ml solution containing DNA from cells of interest,
1.0X Taqman universal master mix (Applied Biosys-
tems, Branchburg, NJ), 900 nM forward and reverse
primers, and 250 nM Taqman probe. The sequences
of the primers and probe used are the following: forward
primer 5’-GACGCCACATGCCTTTCAA-3’; reverse
primer 5’-GCGCCAGCTGCAGGGTTTT- 3’ and
the probe 5’-6FAM-CTCACCTCTGTGCACGGT-
GATA-TAMRA-3’ producing a 131 bp product. As
an internal control measurement, to normalize for the
input DNA, HPRT was amplified in every sample
tested (forward primer 5’- GGATTTGAAATTCCA-
GACAAGTTTGTTG-3’; reverse primer 5’- GTGA-
GAAAAAGAAGCAATTACTTACATTC- 3’, and
the probe 5’- 6FAM-GCCCTTGACTATAATGAA-
TACTTCAGG-TAMRA- 3’). A standard curve was
created, by cloning the Sj fragment into a pGEM-T
Easy Vector (Promega) and the number of Sj copies
present in a given population was calculated by includ-
ing a dilution series of this standard in each PCR exper-
iment. PCR was performed under the following
conditions: 50C for 2 minutes followed by 95C for
10 minutes, after which 50 cycles of amplification
were carried out (95C for 15s, 60C for 1 minute).
For each sample, the Ct-value, defined as the minimal
number of cycles necessary to exceed the threshold,
was measured and applied to the standard curve.
Biol Blood Marrow Transplant 15:662-670, 2009 665BMTof XSCID Dogs using Cultured CD341 Cells.Assessment of Humoral Immune Function
Serum IgG was determined by radial immunodif-
fusion using canine IgG specific plates (Bethyl Lab.
Inc., Montgomery, TX). When serum IgG concentra-
tions reached normal levels, dogs were immunized
with a modified-live canine parvovirus (CPV) and ca-
nine distemper virus vaccine (CDV) and serum IgG
specific antibody titers were determined by either
a passive hemagglutination (for CPV) or serum
neutralization (for CDV) assay by the Cornell
University Veterinary Diagnostic Laboratory.RESULTS
Six XSCID dogs were transplanted with allogeneic
CD341 bone marrow cells from normal donors that
were cultured for either 4.5 days or 18 hours in a cyto-
kine cocktail used for ex vivo retroviral transduction.
Table 1 illustrates the dose of cells and haplotype of
the donor for each of the XSCID recipients. The pu-
rity of the isolated CD341 cells ranged from 94% to
97%. The dose of cells chosen was based on studies us-
ing freshly isolated allogeneic CD341 cells from both
DLA-matched and DLA-haploidentical donors that
result in sustained engraftment of both donor-derived
B and T cells with reconstitution of normal B and
T cell function. Fig. 1 illustrates that T cell reconstitu-
tion as measured by CD45RA1 (naı¨ve) T cells is simi-
lar in XSCID dogs transplanted with freshly isolated
CD341 cells from both DLA-matched and DLA-hap-
loidentical donors at doses of$5  106 cells/kg (range
5 to 40  106/kg). None of the dogs in either experi-
ment received any pretransplant conditioning.
Prior to transplantation, all six dogs had the typical
XSCID phenotype of low to absent peripheral T cells
and normal or elevated numbers of peripheral B cells.
During the first 3 months following transplantation,
all 6 dogs demonstrated an increase in the proportion0
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Figure 1. T cell reconstitution following DLA-matched or haploident-
ical bone marrow transplantation of XSCID dogs. Absolute number of
peripheral CD45RA1 T cells in XSCID dogs following transplantation
with $5 x 106 CD341 bone marrow cells from normal matched
(n5 10) or haploidentical (n5 6) donors.of peripheral T cells (Fig. 2A). Some XSCID dogs, like
some XSCID boys, can develop autologous phenotyp-
ically mature, but nonfunctional, T cells with age
because of peripheral expansion through a gc-inde-
pendent pathway. However, these T cells have an acti-
vated (CD45RA-) phenotype with the dogs remaining
severely T cell lymphopenic and not surviving past 3
months of age. Because T cells derived from trans-
planted stem cells or T cell progenitors would be
expected to develop through a thymic-dependent
pathway and have a naı¨ve (CD45RA1) phenotype, we
examined the CD45 isoform usage in the transplanted
dogs as a measurement of T cell reconstitution.
Between 1 and 1.5 months post transplant the majority
of peripheral T cells in all the dogs expressed a naı¨ve
(CD45RA1) phenotype (Fig. 2B). However, 2 of the
4 dogs transplanted with cells cultured for 4.5 days
showed a rapid conversion to a CD45RA- phenotype
typical of untreated XSCID dogs. These same two
dogs failed to develop normal numbers (.1000/ml)
of CD45RA1 T cells (Fig. 2C). The other two dogs
in this group, R1789 and X299, maintained normal
proportions and numbers of CD45RA1 peripheral
T cells through 8 months post transplant, although
the absolute numbers of CD45RA1 T cells remained
less than normally observed in XSCID dogs
transplanted with freshly isolated CD341 cells. At 8
months post transplant, the proportion and number
of CD45RA1 peripheral T cells started to decline.
The kinetics of T cell reconstitution differed in these
two dogs with one dog, X299, showing a rapid increase
in the number of CD45RA1 peripheral T cells,
whereas the other dog, R1789, showed a more gradual
increase in the number of CD45RA1 peripheral T
cells. Both of the dogs transplanted with cells cultured
for 18 hours developed and sustained numbers of
CD45RA1 peripheral T cells similar to dogs trans-
planted with freshly isolated cells. The CD4/CD8 ra-
tio in the four dogs that successfully engrafted
followed a similar kinetics as seen in XSCID dogs
transplanted with freshly isolated CD341 cells (data
not shown).
Proliferation in response to mitogenic stimulation
was used toassess T cell function in the dogs that success-
fully engrafted. Fig. 3 illustrates that the two dogs trans-
planted with cells cultured for 4.5 days, R1789 and X299,
and both of the dogs transplanted with cells cultured for
18 hours demonstrated normal proliferation.
Thymic function was assessed in all 4 of the dogs
that successfully engrafted using a TREC assay to eval-
uate thymic output. All the dogs showed high levels of
TRECs during the first four months following trans-
plantation (Fig. 4A). The number of TRECs in the
two dogs transplanted with cells cultured for
4.5 days, dogs 1789 and X299, started declining be-
tween 4 to >6 months post transplant. The dogs trans-
planted with cells for 18 hours, dogs 1844 and 1847,
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Figure 2. Longitudinal analysis of T cell reconstitution following bonemarrow transplantation of XSCID dogs with cultured bonemarrowCD341 cells.
Proportion of peripheral T cells (A), and proportion (B) and absolute number (C) of peripheral T cells expressing a naı¨ve (CD45RA1) phenotype in
XSCID dogs following transplantation with CD341 bonemarrow cells following culture for 18 hours or 4.5 days in comparison with 8 dogs transplanted
with freshly isolated CD341 cells in Fig1, which that were incorporated into our breeding program.
666 Biol Blood Marrow Transplant 15:662-670, 2009D. R. Kennedy et al.also showed a decline in TREC levels, however, at
8 months post transplant the TREC levels were higher
than those observed in the dogs transplanted with the
cells cultured for 4 1⁄2 days at 6 months post transplant.
These results contrast with those in two dogs recently
transplanted with with freshly isolated cells, dogs
R1751 and R1752, in whom TREC levels have re-
mained stable for at least 12 months post transplant.
Fig. 4B illustrates the histology of the thymus at
12 months post transplant, showing that dogs trans-
planted freshly isolated cells possess a normal thymic
histology characterized by numerous thymocytes anda well defined cortex and medulla. The dogs trans-
planted with cells cultured for 4.5 days had a thymic
morphology very similar to that of an untreated
XSCID, whereas the thymic morphology of dogs
transplanted with cells cultured for 18 hours, although
not normal, still had an appearance of a normal thymus
with a well defined cortex and medulla.
Serum IgG concentrations in dogs that success-
fully engrafted reached low normal values between 6
to 8 months post transplant (data not shown). These
dogs were immunized with a modified, live vaccine
to CPV and CDV and, in contrast to untreated XSCID
Figure 3. T cell function following bone marrow transplantation. Proliferative response of peripheral blood T cells following PHA stimulation in dogs
R1789, X299, R1844, and R1847 at 4 months post BMT. The results of a normal dog analyzed at the same time are also presented. Percentages represent
the proportion BrdU1 cells.
Biol Blood Marrow Transplant 15:662-670, 2009 667BMTof XSCID Dogs using Cultured CD341 Cells.dogs, demonstrated a significant increase in IgG spe-
cific antibody titers to each virus. All the dogs had
pre-immunization specific IgG antibody titer to
CDV of\1:10 and to CPV of\1:4. Following two
doses of vaccine, the IgG specific antibody titers to
CDV ranged from 1:160 to 1:1280 CDV and from
1:128 and 1:640 for CPV. No adverse reaction to the
vaccine was observed.DISCUSSION
The disappointing results in attempting to dupli-
cate the g-retroviral gene transfer experiments in
mice to large animals and humans in the 1990s were
often attributed to ‘‘low’’ transduction efficiencies.
Therefore, considerable effort was devoted to increas-
ing transduction efficiencies in CD341 cells from large
animals and humans that resulted in the first successful
human clinical gene therapy trial in 1999 [44]. Current
protocols for ex vivo transduction of HSC with
g-retroviral vectors require ex vivo manipulation and
culture of the cells in various cytokine cocktails for
up to 5 days. Numerous murine transplant studies, in-
cluding xenotransplant studies using human CD341
cells in NOD/SCID mice, and nonhuman primate
transplant studies have shown that ex vivo culture of
HSC for as little as 24 to 48 hours may have a detri-
mental effect on their short-term and long-term
engraftment potential, however these studies were
performed in myeloablated recipients [reviewed in45]. Although the NOD/SCID xenotransplant model
has become the ‘‘gold standard’’ for evaluating human
hematopoiesis in vivo, this model is limited because of
it’s short life span precluding long-term studies [46],
and does not support thymopoiesis so T cell develop-
ment cannot be studied [47].
In this study we addressed the effect of ex vivo cul-
turing of normal canine CD341 bone marrow cells un-
der conditions similar to those used for ex vivo gene
transfer on their ability to reconstitute normal T cell
function and sustain long-term thympoiesis in non-
conditioned XSCID dogs following allogeneic BMT.
Although the focus of this study was to address ex
vivo culture conditions used for ex vivo gene therapy,
we chose to perform these studies in an allogeneic
BMT setting as it eliminates one major variable associ-
ated with gene therapy studies, namely the transduc-
tion efficiency of the g-retroviral or lentiviral vector.
This is the first study to address this question in a large
animal model of a relevant human disease and in the
absence of any pre-transplant conditioning, and is
also the first to demonstrate the effect of ex vivo culture
on thymopoiesis.
The dose of cells used in this study was the upper
limit used in our previous studies using freshly isolated
CD341 bone marrow cells [8,48]. Only two of the four
XSCID dogs transplanted with CD341 cells cultured
for 4.5 days successfully engrafted with each dog
showing a different kinetics of T cell reconstitution.
Although both of these dogs developed numbers of
CD45RA1 (naı¨ve) T cells within the range for age-
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Figure 4. Thymus output following bone marrow transplantation. TREC levels in XSCID dogs following transplantation with freshly isolated CD341
cells or CD341 cells cultured for 18 hours or 4.5 days (A). Histologic appearance of the thymus in XSCID dogs one year following transplantation with
freshly isolated bone marrow CD341 cells or CD341 cells cultured for 18 hours or 4.5 days (B).
668 Biol Blood Marrow Transplant 15:662-670, 2009D. R. Kennedy et al.matched normal dogs, they were substantially lower
than that observed in XSCID dogs transplanted with
freshly isolated CD341 bone marrow cells. Both
dogs showed a gradual decline in the proportion and
absolute number of peripheral CD45RA1 T cells to
the lower limits of age-matched normal dogs (.750/
ml) by 12 months following transplantation. These re-
sults differ substantially from those observed in
XSCID dogs successfully immune reconstituted with
freshly isolated CD341 bone marrow cells from both
DLA-matched and haploidentical donors that main-
tain normal numbers of peripheral T cells ranging
from 1950/ml to 2190/ml through 5 to 7.5 years post
transplant [8,48]. In contrast, both XSCID dogs trans-
planted with CD341 cells cultured for 18 hours
successfully engrafted with a robust T cell reconstitu-
tion with sustained numbers of peripheral CD45RA1
T cells similar to that observed using freshly isolated
CD341 cells.
The dogs that successfully engrafted donor cells
exhibited T and B cell function as demonstrated by
a normal T cell proliferative response following mito-
genic stimulation and the ability to produce antigen-
specific IgG antibody following immunization.
Evaluation of thymopoiesis by TREC analysis and
the histologic appearance of the thymus, however,
demonstrated differences between both groups ofXSCID dogs treated with cultured CD341 cells com-
pared with XSCID dogs transplanted with freshly iso-
lated CD341 cells. XSCID dogs transplanted with
freshly isolated CD341 cells exhibit a thymus that
has a normal histiologic appearance and increasing
numbers of TRECS at 12 months post transplant, sug-
gesting active thymopoieis is still occurring. XSCID
dogs transplanted with CD341 cells cultured for 4.5
days showed a rapid decrease in TRECs and a thymus
that had a histologic appearance of a dysplastic XSCID
thymus 12 months post transplant. In contrast, the
XSCID dogs transplanted with CD341 cells cultured
for 18 hours showed a more gradual decrease in
TRECs with a thymus that, although not normal,
had a well-defined cortex and medulla. These results
suggest that the ability to sustain long-term thymopoi-
esis is impaired under culture conditions used for ex
vivo gene therapy, and that ex vivo culturing of the
HSC under conditions used for g-retroviral also
affects their engraftment potential.
Our results are consistent with the results of 21
XSCID boys treated by ex vivo g-retroviral gene ther-
apy [10,13,14,49-52]. Two patients failed to engraft
gene-corrected cells and an additional 4 patients had
suboptimal levels of T cell immune reconstitution.
Long-term follow-up of the 15 patients who reconsti-
tuted normal or low normal gene-corrected T cells
Biol Blood Marrow Transplant 15:662-670, 2009 669BMTof XSCID Dogs using Cultured CD341 Cells.have shown a gradual decline in T cell numbers start-
ing approximately 2 years after treatment with a con-
comitant decrease in CD45RA1 (naı¨ve) T cells
[50-52], suggesting that the ability to sustain long-
term thymopoiesis is impaired under current condi-
tions used for ex vivo g-retroviral gene therapy. These
results can be best explained by the engraftment of
transduced committed T cell progenitors, and proba-
bly few, if any, transduced HSC capable of self-
renewal. If this were the case, the continual production
of new T cells would be expected to decrease over time
as appears to be the case.
Central to optimizing ex vivo gene therapy, is de-
termining culture conditions that maintain both the
engraftment potential and ‘‘stem cell’’ potential of
the transduced (cultured) cells. The true test, however,
of whether these culture conditions preserve stem cell
activity and engraftment potential is evaluating their
performance in vivo, preferably in large animal models
under conditions of no conditioning [16]. For over
50 years, the dog has historically been the pre clinical
animal model for BMT with many of the advances
made in this model being directly transferable to hu-
man clinical BMT protocols [53-57]. A major advan-
tage of using the XSCID dog model to test ex vivo
culture conditions associated with gene therapy is
that BMT can be performed in the absence of any
pre transplant conditioning, thereby eliminating any
potential effects of the conditioning regimen itself on
either the bone marrow or thymic microenvironments.ACKNOWLEDGMENTS
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